Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly : CHMP Recommends Approval of Baricitinib in Atopic Dermatitis

share with twitter share with LinkedIn share with facebook
09/18/2020 | 08:49am EDT

By Michael Dabaie

 

Eli Lilly & Co. and Incyte said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.

The opinion marks the first step toward European regulatory approval for baricitinib, marketed as Olumiant, for patients with atopic dermatitis.

The CHMP opinion is now being referred for action to the European Commission, which grants approval in the European Union. A final decision is expected from the European Commission in the next one to two months, the companies said.

Olumiant is already approved in more than 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis. Lilly has exclusive worldwide development and commercialization rights for baricitinib and some follow-on compounds for patients with inflammatory and autoimmune diseases under a license and collaboration agreement with Incyte.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -1.59% 141.31 Delayed Quote.7.52%
INCYTE CORPORATION -0.80% 88.6 Delayed Quote.1.47%
share with twitter share with LinkedIn share with facebook
All news about ELI LILLY AND COMPANY
09:00aLilly hires external adviser for COVID-19 drug plant problems
RE
08:59aREGENERON PHARMACEUTICALS : Lilly hires external adviser for COVID-19 drug plant..
RE
12:13aEli Lilly Says 1 Manufacturing Plant Underwent FDA General Surveillance Inspe..
RE
10/20SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
10/20THE LAW OFFICES OF FRANK R. CRUZ : Continues Its Investigation of Eli Lilly and ..
BU
10/20INVESTOR ALERT : Law Offices of Howard G. Smith Continues Investigation of Eli L..
BU
10/20ELI LILLY AND COMPANY : - Lilly Declares Fourth-Quarter 2020 Dividend
AQ
10/19GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Continues Inv..
BU
10/19ELI LILLY AND : Lilly Declares Fourth-Quarter 2020 Dividend
PR
10/19WHO says expects to hear more soon on paused COVID-19 antibody trial
RE
More news
Financials (USD)
Sales 2020 23 790 M - -
Net income 2020 6 101 M - -
Net Debt 2020 11 592 M - -
P/E ratio 2020 21,5x
Yield 2020 2,11%
Capitalization 128 B 128 B -
EV / Sales 2020 5,87x
EV / Sales 2021 5,27x
Nbr of Employees 33 625
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 166,35 $
Last Close Price 141,31 $
Spread / Highest target 41,5%
Spread / Average Target 17,7%
Spread / Lowest Target -15,1%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY9.25%130 160
JOHNSON & JOHNSON-0.90%380 575
ROCHE HOLDING AG-2.21%289 156
PFIZER INC.-3.52%208 327
MERCK & CO., INC.-13.94%197 964
NOVARTIS AG-15.38%188 853